within Pharmacolibrary.Drugs.ATC.B;

model B01AB51
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 8.333333333333334e-08,
    adminDuration  = 600,
    adminMass      = 5000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 7.000000000000001e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AB51</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Heparin combinations are preparations containing heparin (an anticoagulant) with one or more additional active substances. Heparin is used primarily for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and during procedures requiring anticoagulation. It is a widely approved and used drug in both prophylaxis and treatment of clotting disorders.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients following intravenous administration of heparin in combination with other agents (e.g., sodium, or in multi-component antithrombotic therapies).</p><h4>References</h4><ol><li><p>Kandrotas, RJ (1992). Heparin pharmacokinetics and pharmacodynamics. <i>Clinical pharmacokinetics</i> 22(5) 359–374. DOI:<a href=\"https://doi.org/10.2165/00003088-199222050-00003\">10.2165/00003088-199222050-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1505142/\">https://pubmed.ncbi.nlm.nih.gov/1505142</a></p></li><li><p>Verstraete, M (1990). Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins. <i>Drugs</i> 40(4) 498–530. DOI:<a href=\"https://doi.org/10.2165/00003495-199040040-00003\">10.2165/00003495-199040040-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1964634/\">https://pubmed.ncbi.nlm.nih.gov/1964634</a></p></li><li><p>Ofosu, FA (1998). Pharmacological actions of sulodexide. <i>Seminars in thrombosis and hemostasis</i> 24(2) 127–138. DOI:<a href=\"https://doi.org/10.1055/s-2007-995831\">10.1055/s-2007-995831</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9579633/\">https://pubmed.ncbi.nlm.nih.gov/9579633</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AB51;
